Genomic Nanosystems Announced Today That It Has Received the Exclusive Patent Rights for Clonal Amplification and Digital PCR (Polymerase Chain Reaction) from Cytonix
Genomic Nanosystems, LLC has received the exclusive patent rights to U.S. patent No. 6,143,496. Patent ‘496 was first to describe methods for detecting single nucleic acid molecules after one amplification step, for amplifying one or more nucleic acids in nano-scale volumes or regions, and for carrying out digital PCR.
In quantitative DigitalPCR(trademark), single DNA or RNA molecules from a sample are isolated and amplified in an excess of miniature chambers, volumes or regions. Following amplification, a count of chambers containing detectable levels of PCR end product is a direct measure of the absolute nucleic acid quantity in the original sample. Conducting DigitalPCR in emulsions (dePCR) allows many millions of PCR reactions to occur in parallel, providing high precision and the ability to resolve rare events.
Another important application of Digital PCR, is clonal template amplification, a vital step in 2nd generation nucleic acids sequencing. According to an editorial in the Journal Nature Methods, PCR is the workhorse of modern molecule biology and digital PCR is its next frontier (Nature Methods 4:869, 2007).
Genomic Nanosystems is developing DigitalPCR products for a wide spectrum of applications, including detection of pathogens, cancer, fetal abnormalities and forensic evidence. Genomic Nanosystems plans to release a DigitalPCR kit this summer for dispersing PCR ready samples into millions of stable micelles in a hydrophobic matrix.
“We're interested in licensing digital PCR technology to further improve the efficiency and effectiveness of PCR testing in the laboratory, and to enhance nucleic acids sequencing,” said Dr. Luke Ratnasinghe, Chief Technology Officer, of Genomic Nanosystems.
Elaine Lanza, Ph.D.